yumab-logo

Autor: Susanne Kuhlendahl

Unlocking intracellular targets with highly specific TCR-like antibodies

Specificity is key to developing safe TCR or TCR-like antibody therapeutics. YUMAB’S novel CHO-display library presents the natural human pHLA repertoire on the cell surface, thereby enabling thorough counter-selections and screenings to identify TCRs or TCR-like antibodies with minimal off-target binding at early stages of drug discovery. This case study explains how our new TCRm […]

Unlocking complex targets with paired antibody libraries

While conventional combinatorial libraries remain highly effective for a wide range of targets and offer significant diversity, paired antibody libraries enable the discovery of more functional antibodies with higher affinities, especially for complex or structurally demanding targets such as glycans. In this case study, we have identified over 1,000 glycan-specific clones using paired libraries compared […]

YUMAB and InSCREENeX get funding for innovative Mammalian Display screening

YUMAB and InSCREENeX are developing an innovative „Mammalian Display“ screening platform to accelerate antibody development. Braunschweig, January 29th, 2025 – YUMAB GmbH, a German biotechnology company specializing in contract research for therapeutic antibodies, announces its collaboration with InSCREENeX GmbH to establish a novel technology for antibody development. As part of the funded project „Mammalian Display,“ […]

Engineering of rare, naturally occurring non-developable antibodies into powerful therapeutics

Rare antibodies with unusual structures and ultra-long CDRs have the potential to bind to difficult-to-access epitopes (e.g., GPCRs, ion channels), and thus offer a unique mode of action. But since they are considered non-developable, they are often excluded from rationally designed antibody libraries or neglected in developability-driven AI selections. This application note demonstrates how tailored […]

youtube-icon
linkedin-icon

YUMAB GmbH